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Abstract
Background: Adjuvant therapy to ORT with probiotic bacteria for infants with acute watery
diarrhea has been under active investigation. Most studies have been done in the developed world
showing benefit only for viral mild gastroenteritis. We evaluated the effect of a milk formula
containing one billion (109) cfu/ml of Lactobacillus casei strain GG (LGG) upon duration and severity
of diarrhea in infants in an environment with more severe acute diarrhea, where etiologic agents
other than rotavirus are involved more frequently, and where mixed infections are more prevalent.
Methods: Male infants aged 3–36 months brought for treatment of acute watery diarrhea of less
than 48 hours were eligible. After rehydration was completed with the WHO's oral rehydration
solution, patients were randomly assigned to receive a milk formula either containing LGG or not.
Stool volume was periodically measured using a devise suited to collect stools separate from urine.
Duration of diarrhea was estimated based on stools physical characteristics.
Results: Eighty nine patients received the placebo milk formula and ninety received the LGG
containing formula. Both groups were comparable in their baseline characteristics. Total stool
output was significantly larger (p = 0.047) in the LGG group (247.8 ml/kg) than in the placebo group
(195.0 ml/kg). No significant differences were found in duration of diarrhea (58.5 hours with LGG
vs. 50.4 hours with placebo), rate of treatment failure (21.1% with LGG vs. 18.0% with placebo),
and proportion of patients with unresolved diarrhea after 120 hours (12.2% with LGG vs. 12.5%
with placebo). The rate of stools with reducing substances after 24 hours of treatment increased
significantly in both groups (from 41.4% to 72.2% with LGG and from 45.9% to 68.0% with placebo).
Conclusion: This study did not show a positive effect of LGG on the clinical course of acute
watery diarrhea. Positive beneficial effects of LGG, as had been reported elsewhere, could have
been masked in our study by worsening diarrhea due to transient lactose malabsorption. Further
studies with low-lactose or non-lactose conveyors of LGG are desirable.
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Background
Diarrheal diseases in the developing world continue to
cause significant morbidity and mortality, especially
when associated with malnutrition [1]. Dehydration,
potassium depletion and acidosis are the main life-threat-
ening complications of the acute losses during watery
diarrhea. More than 25 years of extensive use has demon-
strated that these complications could be effectively
treated or prevented by oral rehydration therapy [2].
However, the oral glucose-electrolyte rehydration solu-
tion such as that recommended by WHO and Unicef nei-
ther shortens the duration of the illness nor reduces the
stool loss and may cause an increase in stool volume at
least during the first hours in children with acute diarrhea
[3]. Optimization of the standard WHO-ORS solution, by
reducing its osmolarity, has been shown to reduce
diarrhea duration, total stool output, and the need for
unscheduled intravenous therapy [4].
Adjuvant therapy to ORT, based on oral administration of
live probiotic bacteria aimed to improve recovery of
infants from acute watery diarrhea, has been under active
investigation [5]. These studies, done in the developed
world, have shown a benefit only for viral mild gastroen-
teritis. Isolauri et al have shown that oral bacterial therapy
with Lactobacillus casei strain GG (LGG) reduces both the
severity and duration of acute non dehydrating rotavirus
enteritis [6]. Another trial in Karelia republic, LGG was
shown to decrease the duration of acute diarrhea in chil-
dren with viral acute diarrhea but not in those with bacte-
rial diarrhea [7]. In a multicenter study carried out in
Europe, LGG was administrated in a hypotonic oral rehy-
dration solution to children with acute diarrhea, showing
that it was safe and resulted in shorter duration of
diarrhea, less chance of a protracted course, and faster dis-
charge from the hospital [8].
Limited information is available on the potential role of
LGG in infants living in the developing world, with more
severe acute watery diarrhea [9], where etiologic agents
other than rotavirus are involved more frequently and
where mixed infections are more prevalent [10]. We con-
ducted this study aimed to assess the effect of a milk for-
mula containing Lactobacillus casei strain GG (LGG) on the
duration and severity of diarrhea in children with acute
watery diarrhea from our hospital. The study was con-
ducted in the Rehydration Unit of Cayetano Heredia Hos-
pital in Lima, Peru from September 1991 to June 1992.
The study protocol and Consent Form were reviewed and
approved by the Ethical Committee of Cayetano Heredia
University in compliance with the Helsinki Declaration.
Methods
Study population
Male infants 3–36 months of age brought for treatment
because of acute diarrhea to the Rehydration Unit of
Cayetano Heredia Hospital, Lima during September 1991
to June 1992 were eligible for the study if they met the fol-
lowing criteria: (a) a history of three or more watery stools
per day for less than 48 hours, (b) no bloody stools at the
moment of first examination, (c) clinical signs of dehy-
dration, (d) no clinical features of hypovolemic shock, (e)
no clinical signs of a coexisting acute systemic illness (i.e.,
meningitis, sepsis, pneumonia) or a recognized chronic
disease such as pulmonary tuberculosis, and (f) no history
of current antibiotic or antidiarrheal medication use.
Patients 3–6 months old were considered for the study
only if they were not on exclusive breastfeeding. Patients
were not selected if their weight for age was less than 60%
of the median weight for age established by the National
Center for Health and Statistics (NCHS) [11]. Only
patients whose parent or legal guardian was willing and
able to give written informed consent were admitted to
the study. Only male patients were selected in order to
facilitate separate collection of stools and urine. The study
size was calculated expecting a 33% reduction in duration
of diarrhea and mean volume of diarrhea stool for a sig-
nificance level of 0.05 and a power of 80%.
Study design
Infants fulfilling the admission criteria were randomly
assigned to a double-blind comparison of a milk formula
containing 109  cfu/ml of Lactobacillus casei strain GG
(LGG) or a similar milk formula not containing LGG.
Both formulas were of identical looking and tasting. Both
milk formulas were provided by the manufacturer (Valio
Ltd, Helsinki, Finland) as milk powder to reconstitute
with water. They were given in bottles, appropriately
labeled and number-coded for each child to secure the
double-blind design. The actual assignment of children to
their study numbers was made at the time of their enroll-
ment into the study. Each child admitted into the study
was allocated to either treatment group by restricted rand-
omization using random permuted blocks. The codes
were prepared in Finland and kept in sealed envelopes in
Lima.
Baseline assessment
A clinical history and physical examination was com-
pleted upon admission to identify the patient, to deter-
mine the duration, type and severity of his diarrhea, to
assess associated clinical features (fever, vomiting, dehy-
dration, abdominal pain, distension), and to establish the
nutritional status and previous dietary regimen of the sub-
ject. Blood for determination of serum sodium, potas-
sium, chloride, glucose and bicarbonate, blood urea
nitrogen, microhematocrit and plasma specific gravityBMC Pediatrics 2004, 4:18 http://www.biomedcentral.com/1471-2431/4/18
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was drawn from each patient before starting treatment. A
routine urine analysis was also made. Fecal samples or rec-
tal swabs taken at admission were transported in Cary-
Blair transport medium to Cayetano Heredia University
Microbiology Laboratory for primary isolation and identi-
fication of bacterial enteropathogens. A separate vial con-
taining phosphate buffer saline was used to transport fecal
specimens for rotavirus examination.
Microbiologic methods
Specimens were cultured for Salmonella, Shigella, E. coli
and Vibrios by standard direct and enrichment enteric
media. Campylobacter  was selectively cultured on sheep
blood agar containing Butzler's antibiotic supplement
and Aeromonas on ampicillin blood agar preceded by over-
night enrichment in alkaline peptone water. Five lactose
fermenting colonies of E. coli isolates per patient were
serotyped according to standard methods using polyva-
lent sera for the recognition of enteropathogenic E. coli.
Detection of Rotavirus was made by ELISA method using
Rotazime®. Identification of enterotoxigenic strains of E.
coli was not done. Details of the microbiologic methods
used in this study are described in detail elsewhere [10].
Rehydration
The degree of dehydration was assessed clinically. Dehy-
dration was corrected and then fluid balance maintained
using the oral rehydration salts (ORS) in its standard
WHO's recommended formulation, following the WHO
Guidelines [12]. Briefly, each child was given approxi-
mately 100 ml/kg of ORS during the first four hours. The
ORS was administered in frequent sips using a spoon or
by nasogastric tubes if vomit or stool output rates were
high. Children were not given other fluid or foods during
this period. Upon completion of this period, on-going
fecal losses were replaced with the same solution, on a
volume to volume basis until diarrhea ceased.
Administration of the study formula
Once dehydration was corrected, feeding, including
administration of the assigned study formula was initi-
ated. The first dose of the assigned study formula was
administered as soon as rehydration was completed and
subsequent doses were given every four hours until cessa-
tion of diarrhea or for a maximum of five days. The for-
mula was prepared immediately before administration of
each dose by a specially trained nurse that was exclusively
working for the study. Measuring spoons provided by the
manufacturer were used and the formula powder was kept
refrigerated all the time once the container was opened.
Before use, the sachets with the study formulas were kept
in a -20°C refrigerator. The formula powder was diluted
in warm boiled water as to provide 670 Kcal per liter. The
amount of formula given to each child was calculated
based on the child's body weight, each child being given
150 ml/kg/day to a maximum of 1000 ml/day. On aver-
age, each serving of 100 ml will supply 1011 cfu of LGG for
those receiving the formula containing LGG. Administra-
tion of the formula was by bottle and not compulsive. If
the child refused to drink the formula after reasonable
attempts, no extraordinary methods, like delivery via
nasogastric tubing, were used; in this situation the for-
mula was offered again four hours later.
Other foods given
Patients under six months of age were fed only the ran-
domly assigned study formula to provide a daily caloric
intake of at least 100 Kcal/kg (in a volume of 150 ml/kg/
day). No other foods were given for these under six
months patients. Older patients were fed the assigned for-
mula ad libitum for a maximum of 1000 ml/day. Caloric
requirements were completed with a blended soft baby
food prepared from fresh ingredients (chicken breast, rice,
carrots, squash, potatoes, and vegetable oil), by the Hos-
pital's Nutrition Department. This soft baby food pro-
vides 1 Kcal per gram (approximately, 10% of its calories
as protein, 45% as carbohydrates and 45% as fats). A total
of at least 100 Kcal/kg/day (including the calories pro-
vided by the study formula) were offered to these
children.
Measurement of clinical outcomes
All oral intake (ORS, study formula, breast milk, plain
water, soft baby food) as well as urine, stool and vomitus
volume were strictly measured and recorded during hos-
pitalization. For this purpose patients were put on meta-
bolic beds (which have a hole in the mattress were a
container was placed to allow direct stool collection). A
urine collection bag was fitted to avoid contamination of
stools with urine and to measure the urine volume. After
the first 72 hours, differential weight of dry and soiled dia-
pers was used instead the metabolic bed to determine
stool weight if the previous observed purging rate was
below 5 ml/kg/hour. Blood analyses taken at admission
were repeated at 24 hours. Stool examination for pH, glu-
cose, reducing substances, leukocytes and microscopic fat
were performed at admission, 24, 72 hours and at dis-
charge. Urine specific gravity was determined every 24
hours until discharge.
Criteria for stopping treatment and discharging the 
patient
Patients were discharged from the study 24 hours after
cessation of diarrhea, or at the end of five days from
admission, or at the time treatment failure occurred. At
discharge each patient was categorized as have completed
the trial, as a treatment failure, as an unresolved diarrhea
situation, or as a withdrawal.BMC Pediatrics 2004, 4:18 http://www.biomedcentral.com/1471-2431/4/18
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Primary outcomes
• Rate of treatment failure: proportion of patients in each
study group who have recurrence or continued presence
of more than 5% dehydration, worsening electrolyte
abnormalities, no weight gain since admission, develop-
ing of ileus or severe diarrhea defined as a purging rate in
excess of 10 ml/Kg/hr in two consecutive 4-hour periods.
• Rate of unresolved diarrhea after five days of treatment:
proportion of patients in each study group with continu-
ing diarrhea after five days of treatment.
• Duration of diarrhea: time in hours from admission
until cessation of diarrhea
• Duration of hospitalization: time in hours from admis-
sion until discharge from hospital. Patients with treat-
ment failure are excluded.
• Total stool output: volume of diarrheic stools collected
from admission until cessation of diarrhea or for a maxi-
mum of 120 hours if diarrhea continues, expressed in mil-
liliters per kilogram of body weight.
• Total intake of oral rehydration solution: volume of ORS
taken from admission until cessation of diarrhea or for a
maximum of 120 hours if diarrhea continues, expressed
in milliliters per kilogram of body weight.
Secondary outcomes
• Total study formula intake: volume of study formula
taken from admission until cessation of diarrhea or for a
maximum of 120 hours if diarrhea continues, expressed
in milliliters per kilogram of body weight.
• Total energy intake: energy from all sources (ORS, for-
mula) taken from admission until cessation of diarrhea or
for a maximum of 120 hours if diarrhea continues,
expressed in kilocalories per kilogram of body weight.
• Total volume of vomitus: volume of vomitus collected
each day from admission until cessation of vomitus or for
a maximum of 120 hours, expressed in milliliters per kil-
ogram of body weight.
• Total volume of urine: volume of urine collected each
day from admission until cessation of diarrhea or for a
maximum of 120 hours, expressed in milliliters per kilo-
gram of body weight.
Working definitions
The following definitions were used for this study:
• Carbohydrate malabsorption: stool sample giving a pos-
itive reaction for reducing substances (0.75 g % or above).
• Cessation of diarrhea: passage of formed stool or pas-
sage of no stool for 12 consecutive hours.
• Early withdrawal: patient who (a) developed a compli-
cating illness, (b) presented bloody diarrhea after admis-
sion and before five days of treatment, (c) was
prematurely discharged under request of his parent or
legal guardian, or (d) had any protocol violation or non-
compliance.
Statistical analysis
The data, initially collected in pre-coded forms, were
entered in a database organized with a relational model
under Fox Pro® v. 1.02 (Dbase® compatible formats) using
a data entry program with on-line checking. The data was
checked again in batch mode and finally transferred to
EpiInfo® for Windows® v. 3.01 (November 2003) where
the tabulations and statistical analysis were performed.
Letters (A or B, maintaining blindly the treatment group
assignment) identified treatment groups until all statisti-
cal analysis was completed. Only after completing the
analysis investigators unblinded the treatment assign-
ment. Baseline and outcome two-way comparisons were
made between the two treatment groups. A 5% level of
significance for statistical tests was set in advance for all
comparisons. Chi-square Yates corrected was used to com-
pare discrete variables. One way analysis of variance was
performed for continuous variables. Data from patients
prematurely withdrawn from the study was included in
the analysis up to the time of withdrawal (intention-to-
treat analysis).
Results
A total of 179 patients were admitted into the study, 90 in
the LGG group and 89 in the control group. Nineteen
patients, eight from the LGG group and 11 from the con-
trol group, were prematurely withdrawn from the study
(figure 1) because of either one of the following reasons:
bloody stools within the first 24 hours after admission
(11 patients); parental non-compliance (four patients);
no diarrheal stools passed within the first 24 hours since
admission (two patients); typical severe cholera-like
diarrheal disease improperly included (one patient); and
severe systemic infection present but not recognized at
admission (one patient).
Baseline characteristics
Table 1 presents the baseline characteristics of patients
upon admission. The treatment groups were comparable
in age, nutritional status, and other clinical and laboratory
variables. Marginal differences were found, however, in
stool output during the first four hours of the rehydration
phase, before administration of the study formula. The
LGG group was thus comprised by slightly more severe
cases. Table 2 shows stool microbiology and parasitologyBMC Pediatrics 2004, 4:18 http://www.biomedcentral.com/1471-2431/4/18
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at admission. The distribution of enteropathogens was
similar between both groups, except for rotavirus which
was found more frequently in the placebo group (39.3%)
than in the LGG group (24.4%) with a marginal statistical
significance for the difference (p = 0.052).
Table 1: Clinical and laboratory features on admission
Placebo group N LGG group N P
Age (months) 14.7 ± 6.4 89 14.9 ± 7.5 90 0.878
Duration of diarrhea before admission (h) 29.5 ± 14.9 89 28.8 ± 14.9 90 0.733
N° of stool motions 24 h before admission 6.6 ± 3.2 89 7.5 ± 3.9 90 0.101
N° of patients with vomitus 24 h before admission 64 (71.9%) 89 66 (73.3%) 90 0.963
N° of patients with fever 24 h before admission 39 (43.8%) 89 43 (47.8%) 90 0.703
Clinical dehydration 89 90 0.165
Mild 48 (53.9%) 36 (40.0%)
Moderate 40 (44.9%) 52 (57.8%)
Severe 1 (1.1%) 2 (2.2%)
% of weight gain after rehydration 3.0 ± 2.2 89 3.1 ± 2.3 90 0.763
Fever at admission (≥ 37.5°C) 16 (18.0%) 89 14 (15.9%) 88 0.868
Weight for height* 94.8 ± 9.3 89 94.1 ± 7.6 90 0.551
Height for age* 88.9 ± 12.1 89 97.2 ± 3.7 90 0.546
Weight for age* 88.9 ± 12.1 89 88.9 ± 10.8 90 0.952
Stool output (ml/kg) first 4 h (rehydration phase) 14.4 ± 12.4 89 18.1 ± 16.1 90 0.085
Hematocrit (%) 35.0 ± 4.2 89 35.5 ± 3.8 90 0.426
Plasma specific gravity 1.028 ± 0.002 89 1.028 ± 0.002 90 0.769
Serum Na+ (mEq/l) 136.6 ± 4.7 89 136.4 ± 4.6 87 0.770
Serum K+ (mEq/l) 4.0 ± 0.7 89 4.0 ± 0.7 87 0.985
Serum Cl (mEq/l) 102.5 ± 5.2 89 102.6 ± 5.4 87 0.874
Serum total CO2 (mmol/l) 14.0 ± 3.9 88 14.0 ± 3.9 87 0.971
Blood urea nitrogen (mg/dl) 13.1 ± 10.5 70 11.4 ± 6.6 73 0.253
Blood glucose (mg/dl) 107.5 ± 33.4 88 106.5 ± 35.9 88 0.848
N° of patients with fecal leukocytes (> 20 PMN/hpf) 30 (34.5%) 87 21 (23.6%) 89 0.154
N° of patients with microscopic fat 56 (64.4%) 87 52 (58.4%) 89 0.513
Fecal pH 6.3 ± 1.1 87 6.6 ± 1.1 89 0.126
N° of patients with CHO malabsorption 39 (45.9%) 85 36 (41.4%) 87 0.659
* % of NCHS median
Values are mean ± SD or n (%)
Table 2: Stool microbiology and parasitology at admission
Placebo group N LGG group N P
Rotavirus 33 (39.3%) 84 22 (24.4%) 90 0.052
EPEC 12 (17.6%) 68 9 (13.2%) 68 0.635
Vibrio cholerae 7 (8.0%) 88 11 (12.4%) 89 0.471
Campylobacter sp. 6 (6.8%) 88 9 (10.1%) 89 0.605
Shigella sp. 9 (10.2%) 88 4 (4.5%) 89 0.241
Aeromonas sp. 2 (2.3%) 88 1 (1.1%) 89 0.992
Salmonella sp. 0 (0.0%) 88 1 (1.1%) 89 0.995
Negative microbiology 25 (36.8%) 68 32 (47.1%) 68 0.452
Cryptosporidium parvum 6 (7.0%) 86 2 (2.2%) 89 0.256
Giardia lambliae 2 (2.3%) 86 3 (3.4%) 89 0.969
Strongyloides stercolaris 1 (1.2%) 86 0 (0.0%) 89 0.986
Trichomonas sp. 0 (0.0%) 86 2 (2.2%) 89 0.492
Negative parasitology 77 (89.5%) 86 82 (92.1%) 89 0.738
Negative microbiology and parasitology 22 (35.5%) 62 30 (44.8%) 67 0.371
No patients were found positive for the following parasites: Ascaris, Enterobius, Trichuris, E. hystolytica, Ancylostoma, Necator.
ETEC identification was not done
Values are n (%)BMC Pediatrics 2004, 4:18 http://www.biomedcentral.com/1471-2431/4/18
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Stool purging reduction
The mean total stool output (Table 3) was lower in the
placebo group (195.0 ml/kg) than in the LGG group
(247.8 ml/kg) with a marginal statistical significance for
the difference (p = 0.047). The difference between means
in total stool output was -52.8 ml/kg, with 95% confi-
dence limits between -105.4 to -0.2 ml/kg.
Duration of diarrhea
The proportion of patients with unresolved diarrhea after
120 hours was similar in both treatment groups (table 3).
For those patients that ceased diarrhea during the study
period the mean duration of diarrhea was similar between
groups (table 3). The difference between means in
duration of diarrhea was 8.1 hours with 95% confidence
limits between -19.6 hours to 3.4.
Blood chemistry
No patient had to be withdrawn from the study because
of worsening blood chemistry abnormalities.
Carbohydrate malabsorption
The proportion of patients with carbohydrate malabsorp-
tion 24 hours after admission into the study was high
although not different between the treatment groups
(table 4). However, the rate of carbohydrate malabsorp-
tion after 24 hours of treatment increased significantly in
both treatment groups with respect to admission (table
4). The pH of stools at 24 hours after admission is also sig-
nificantly lower in both groups compared to the pH at
admission, a result consistent with worsening carbohy-
drate malabsorption (table 4).
No adverse effects due to the study formula were notice in
either group during the study.
Discussion
Children included into this study probably represent the
type of patients with diarrheal disease most frequently
seen at a health service in Peru before the cholera
epidemic of 1991. They were infants under two years of
age, with an episode of acute watery diarrhea, presenting
with signs of mild to moderate dehydration and a slight
compromise of the nutritional status. Thus, we can con-
clude that the results of this study can be applied to most
cases of acute watery non-cholera diarrhea seen in this
population setting.
The comparison of baseline characteristics showed no sig-
nificant differences between groups. Marginal differences
(not statistically significant) were observed in two varia-
bles that measure severity of illness: stool frequency 24
hours before admission and stool output during rehydra-
tion phase. Both were higher in the LGG group. Other
indicators of severity, like clinical estimate of dehydra-
tion, percentage of weight gain after rehydration and pro-
portion of patients with vomitus before admission, were
similar between both groups. On the other hand, there
were more cases (not statistically significant) of rotavirus
in the placebo group than in the LGG group. In order to
make sure that the groups were in fact comparable, we
perform the statistical adjustment for these variables using
multiple regression analysis and found no association
with the principal outcomes (results of this analysis are
not shown in the report).
In more than 55% of patients an enteropathogen could be
identified. This figure could be higher because studies for
ETEC were not done. The most prevalent agents were rota-
virus (30.7%), EPEC (11.7%), Vibrio cholerae (10.1%) and
Campylobacter sp. (8.4%), with an important proportion of
patients having mixed infections. These findings differ
considerably from those of the Finnish clinical trial in
which LGG was also tested for efficacy in reducing acute
infantile diarrhea [6]. In the Finnish trial, rotavirus
accounted for more than 80% of diarrheal cases, with no
cases of bacterial diarrhea. A setting of greater diversity of
etiologic agents and frequently co-pathogen association is
perhaps more representative of developing countries [10].
The first topic to be discussed here is the high proportion
of patients that did not recovered optimally during the
trial, a condition that did not depend on the assigned
treatment group. About 12% of patients had an unre-
solved diarrhea and an additional 20% were classified as
treatment failures, mostly due to severe diarrhea. In two
clinical trials conducted at our unit similar rates were
found. For instance, in a clinical trial designed to test the
clinical efficacy of a citrate-based ORS in children with
acute watery diarrhea, patients who received standard
therapy (WHO-ORS) had a treatment failure rate of about
24% [13]. This rate was 40% if only rotavirus associated
diarrhea was considered. In another study, in which a
chicken soup-based ORS was evaluated for children with
similar characteristics (not published), 15.4% treatment
failure rate for all subjects standard and 20% for those
with rotavirus was observed. In the Finnish study, all chil-
dren recovered before 5 days and no treatment failures
were reported [6]. This striking difference could be
explained in part by dissimilar etiologies as was men-
tioned above. Bacterial diarrhea and infection with more
than one pathogen might produce a more severe illness.
The nutritional status is also important to explain the dif-
ference. It has been well established from studies in devel-
oping countries that diarrhea lasts longer in poorly
nourished children [14]. This difference seems to be
important even when only slight malnutrition is present,
as is the case for the patients admitted into this study.BMC Pediatrics 2004, 4:18 http://www.biomedcentral.com/1471-2431/4/18
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Except for total stool output (which showed a marginal
statistical significance), no significant differences in the
principal outcomes between groups were found. Duration
of diarrhea, duration of hospitalization, and total ORS
intake were not significantly different between the experi-
mental and placebo group. The mean volume of formula
(and of lactose) administered to children was the same for
both groups. The confidence limits of the difference
between the two groups indicate that a maximum reduc-
tion on duration of diarrhea of 6.7% attributable to the
LGG formula could have been detected with the sample
size of this study. These numbers indicate that the study
does have a sample size sufficient to reject a type II error.
No positive effects of treatment could be demonstrated as
opposed to Isolauri's experience in Finland [6]. The dose
factor could not explain the difference between the two
studies. The dose of LGG in Isolauri's study was 2 × 1010–
11 cfu per day [6]. The dose of LGG in our study was 6–8 ×
1011 cfu per day, well above the threshold dose of 10 bil-
lion cfu suggested as most effective [15]. Viability of the
Lactobacillus GG in the sachets while stored in Lima was
not confirmed bacteriologically.
There were slightly fewer cases of rotavirus in the LGG
group than in the placebo group (24.4% vs. 39.3%),
although the difference was not statistically significant.
LGG appears to be more effective in viral than in bacterial
diarrhea [8]. These facts could explain in part the lack of
beneficial effect of LGG in our study. It is possible that
LGG was not able to colonize the gut of our patients in the
presence of bacterial pathogens. Although colonization
has been documented during rotavirus diarrhea in chil-
dren [16], to our knowledge this ability has not been dem-
onstrated when other intestinal pathogens are involved.
Colonization properties of LGG in patients with bacterial
enteritis would deserve further studies.
Our study clearly shows that the rate of carbohydrate mal-
absorption raised in both treatment groups from 43.6% at
admission to 70.1% 24 hours later. The amount of lactose
Table 3: Clinical outcomes
Placebo group N LGG group N P Difference between means
Discharge condition 89 90
Early withdrawal 11 (12.4%) 8 (8.9%) 0.609
Treatment failure 16 (18.0%) 19 (21.1%) 0.734
Cessation of diarrhea 51 (57.3%) 52 (57.8%) 0.931
Unresolved diarrhea 11 (12.45%) 11 (12.2%) 0.842
Mean duration of diarrhea (hours)* 50.4 ± 28.0 51 58.5 ± 30.2 52 0.157 -19.6 to 3.4
Mean duration of hospitalization (hours)** 74.7 ± 33.7 62 81.2 ± 32.6 63 0.280 -18.4 to 5.4
Total stool output (ml/kg) 195.0 ± 171.9 89 247.8 ± 180.2 90 0.047 -105.4 to -0.2
Total oral rehydration solution intake (ml/kg) 236.5 ± 195.6 89 272.8 ± 188.1 90 0.208 -93.7 to 21.1
Total study formula intake (ml/kg) 215.5 ± 136.3 89 231.5 ± 136.6 90 0.435 -56.8 to 24.8
Total energy intake (Kcal/kg)§ 220.7 ± 140.4 89 247.4 ± 143.0 90 0.209 -69.1 to 15.7
Total volume of vomitus (ml/kg) 27.6 ± 45.5 89 27.4 ± 33.9 90 0.968 -11.8 to 12.2
Total volume of urine (ml/kg) 81.5 ± 65.2 89 87.1 ± 69.4 90 0.579 -25.7 to 14.5
* For patients who ceased diarrhea before 120 hours.
** Patients with treatment failure or early withdrawals are excluded.
§ Calculated from calories provided by study formula, soft foods, breastmilk, and oral rehydration solution.
Values are mean ± SD, n (%), or 95% confidence limits.
Table 4: Comparison of stool characteristics at admission and 24 hours after
Admission N 24 h later N P
Fecal pH
Placebo group 6.3 ± 1.1 87 5.9 ± 0.8 76 0.014
LGG group 6.6 ± 1.1 89 6.1 ± 0.9 74 0.004
CHO malabsorption
Placebo group 39 (45.9%) 85 51 (68.0%) 75 0.008
LGG group 36 (41.4%) 87 52 (72.2%) 72 < 0.001
Values are mean ± SD or n (%)BMC Pediatrics 2004, 4:18 http://www.biomedcentral.com/1471-2431/4/18
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offered to patients in this study was much higher than in
the usual feeding regimen at our unit (10.5 g/kg/day vs.
3.7 g/kg/day, respectively). Although to some investiga-
tors lactose intolerance is becoming a decreasing problem
[17], it is clear from these data that lactose malabsorption
as a factor cannot be dismissed. We had consistently
found a high proportion of patients with carbohydrate
malabsorption in all similar studies conducted in our
unit. Thus, one possible explanation for the lack of effi-
cacy of LGG in our patients is that worsening diarrhea due
to lactose malabsorption could have masked any benefi-
cial effect of the LGG. If this is true, then reducing the lac-
tose content of the formula might reveal a positive effect.
Another option is to deliver the LGG in suitable non-lac-
tose containing infant food that could be given to
diarrheic children as part of their treatment. Carefully
conducted studies might prove this hypothesis.
Conclusions
Both groups were comparable in their baseline character-
istics. Marginal differences were found in variables that
measured severity of illness before treatment. Total stool
output was slightly higher in the LGG group reaching a
marginal statistical significance. No significant differences
in the other principal outcome variables were found
between treatment groups. The proportion of patients
with unresolved diarrhea after 120 hours was similar in
both treatment groups. For those patients that ceased
diarrhea during the study period the mean duration of
diarrhea was similar between groups. The rate of carbohy-
drate malabsorption after 24 hours of treatment increased
significantly in both treatment groups.
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